Crinetics Pharmaceuticals Reports Positive Top-Line Results from CRN04777 Phase 1 Study Multiple-Ascending Dose Cohorts
30. März 2022 16:01 ET
|
Crinetics Pharmaceuticals, Inc.
Results Further Support Clinical Proof-of-Concept for CRN04777 by Showing Dose-Dependent Decreases in Fasting and Sulfonylurea-Induced Insulin Secretion Management Hosting Webcast and Conference Call...
Crinetics Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
08. Mai 2020 09:01 ET
|
Crinetics Pharmaceuticals, Inc.
Reported positive interim results for the ACROBAT Edge Phase 2 trial of oral paltusotine in the treatment of acromegaly Completed successful public offering raising net proceeds of $107.9 million ...
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
15. April 2020 00:21 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 15, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
09. März 2020 16:10 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference
19. Februar 2020 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Rezolute Initiates Phase 2b Clinical Trial of Lead Candidate RZ358 in Congenital Hyperinsulinism
10. Februar 2020 08:30 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced the initiation of the RIZE study (RZ358-606), a Phase 2b clinical...
Rezolute to Present at BIO CEO & Investor Conference 2020
27. Januar 2020 08:30 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced an upcoming presentation regarding the company’s clinical...
Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
02. Januar 2019 16:05 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals to Participate in Piper Jaffray 30th Annual Healthcare Conference
20. November 2018 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
13. November 2018 16:05 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...